{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:57:30Z","timestamp":1782284250406,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20171448"],"award-info":[{"award-number":["BK20171448"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2187706"],"award-info":[{"award-number":["2187706"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["121877061"],"award-info":[{"award-number":["121877061"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejphar.2024.176716","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T10:39:36Z","timestamp":1717670376000},"page":"176716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms"],"prefix":"10.1016","volume":"977","author":[{"given":"Amin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13578-021-00724-z","article-title":"The cGAS-STING pathway: more than fighting against viruses and cancer","volume":"11","author":"Bao","year":"2021","journal-title":"Cell Biosci."},{"issue":"13","key":"10.1016\/j.ejphar.2024.176716_bib2","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/2159-8290.CD-20-0556","article-title":"Outlook for new CAR-based Therapies with a Focus on CAR NK cells: what Lies beyond CAR-engineered T cells in the Race against cancer","volume":"11","author":"Daher","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12765","article-title":"STING pathway agonism as a cancer therapeutic","volume":"290","author":"Flood","year":"2019","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176716_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.ejphar.2024.176716_bib8","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2024.176716_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"25","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eng.2018.11.015","article-title":"Natural killer cell-based immunotherapy for cancer: Advances and Prospects","volume":"5","author":"Hu","year":"2019","journal-title":"Engineering"},{"key":"10.1016\/j.ejphar.2024.176716_bib11","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"14","key":"10.1016\/j.ejphar.2024.176716_bib12","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.bmc.2018.06.020","volume":"26","author":"Lei","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejphar.2024.176716_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1039\/C8OB02668H","article-title":"Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer","volume":"17","author":"Lei","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2024.176716_bib15","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","article-title":"Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response","volume":"49","author":"Marcus","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.ejphar.2024.176716_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.immuni.2017.09.020","article-title":"cGAS Micro-Manages Genotoxic stress","volume":"47","author":"Motwani","year":"2017","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.ejphar.2024.176716_bib18","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejphar.2024.176716_bib19","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176716_bib20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/sciimmunol.aaz2738","article-title":"NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists","volume":"5","author":"Nicolai","year":"2020","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA damage and cancer immunotherapy: a STING in the Tale","volume":"80","author":"Reisl\u00e4nder","year":"2020","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.ejphar.2024.176716_bib23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2024.176716_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","article-title":"The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells","volume":"616","author":"Sumit","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejphar.2024.176716_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101143","article-title":"Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action","volume":"33","author":"Wudhikarn","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"7555","key":"10.1016\/j.ejphar.2024.176716_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature14493","article-title":"Chromothripsis from DNA damage in micronuclei","volume":"522","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ejphar.2024.176716_bib29","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41423-021-00732-6","article-title":"Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"22","key":"10.1016\/j.ejphar.2024.176716_bib30","first-page":"22949","article-title":"In vitro and in vivo efficacy of the novel oral proteasome inhibitor NNU546 in multiple myeloma","volume":"12","author":"Zhou","year":"2020","journal-title":"Aging (Albany NY)"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924004047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T19:03:00Z","timestamp":1719687780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924004047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"alternative-id":["S0014299924004047"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176716","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteasome inhibitors FHND6091 enhance the ability of NK cells to kill tumor cells through multiple mechanisms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176716"}}